In vitro diagnostics serving the fight against infectious diseases

Image Têtière


separator_grey

bioMérieux

Euronext-listed company, 59% owned by Institut Mérieux

location_bmx
Marcy l’Etoile
(near Lyon, France)

Areas of activity

In vitro diagnostic solutions (reagents, instruments, software, and services) for clinical and industrial applications

Customers

medical testing and private research or hospital laboratories, industrial quality control laboratories

activity_bmx19

bio-industrial production sites and 20 R&D sites

country_bmx
Present in more than

150

countries

collaborators_bmx
close to

9,500

employees

money_bmxSales in 2015

€1,965 M


separator_grey

A GLOBAL PLAYER
IN IN VITRO DIAGNOSTICS

bioMérieux’s mission is to improve global public health through in vitro diagnostics.

The company focuses on two main areas:

  • Clinical diagnostics for infectious diseases primarily, as well cardiovascular emergencies
  • Industrial microbiology

bioMérieux develops, produces, and markets diagnostic systems including:

  • Reagents needed to detect, identify, and quantify pathogens
  • Instruments to automate these tests
  • Software to process and interpret laboratory tests
  • Personalized services for medical testing and industrial control laboratories.

With more than 50 years of experience, bioMérieux is now a major player in the fields of in vitro diagnostics and the fight against infectious diseases. The company is a world leader in clinical microbiology and industrial microbial control. Its extensive international network make it possible to take on diseases that cut across borders and support its clients all over the world.

 

separator_blue

separator_grey

PIONEERING
DIAGNOSTICS

Thanks to its experience and its international R&D programs, bioMérieux can provide health professionals and industries with innovative tools to improve tomorrow’s health care:
  • Point-of-care diagnostic solutions that are better integrated into treatment time
  • High medical-value tests that provide quicker results and are particularly effective in the fight against multi-drug resistant bacteria
  • A so-called syndromic approach to molecular diagnostics that uses a single test to target several bacteria, fungal infections, and parasites that could cause a particular set of symptoms (diarrhea, respiratory diseases, meningitis, etc.)
  • Companion diagnostic tests for personalized medicine based on the patient’s genetic profile
  • A large range of solutions to prevent and determine the source of contamination in agri-food, cosmetic and biopharmaceutical products to protect consumers’ health
  • Applications for veterinary medicine, reflective of a comprehensive approach to health care that breaks down barriers between humans and animals

separator_blue

separator_grey

www.biomerieux.com